Anacor Pharmaceuticals to Hold Conference Call Tomorrow, January 29, 2013 at 8AM ET to Discuss Preliminary Results from the

  Anacor Pharmaceuticals to Hold Conference Call Tomorrow, January 29, 2013 at
  8AM ET to Discuss Preliminary Results from the First Phase 3 Study of
  Tavaborole for the Treatment of Onychomycosis

Business Wire

PALO ALTO, Calif. -- January 28, 2013

Anacor Pharmaceuticals (NASDAQ:ANAC) will release preliminary results from the
first of two Phase 3 studies of tavaborole for onychomycosis tomorrow, January
29, 2013 at approximately 7:00 a.m. ET. The announcement will be followed by a
conference call at 8:00 a.m. ET to discuss the results.

The call can be accessed by dialing (877) 291-1367 (domestic) and (914)
495-8534 (international) five minutes prior to the start of the call. The call
will also be webcast live and can be accessed on the Events and Presentations
page, under Investors, on the company’s website at www.anacor.com and will be
available for three months following the call.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to tavaborole and
AN2728, respectively, and AN3365 (formerly known as GSK2251052, or GSK‘052),
a systemic antibiotic for the treatment of infections caused by Gram-negative
bacteria, which previously was licensed to GlaxoSmithKlineLLC, or GSK. GSK
will be returning all rights to the compound to us and we are considering our
options for further development, if any, of this compound. We have discovered
three other compounds that we have out-licensed for further development — two
compounds for the treatment of animal health indications that are licensed to
Eli Lilly and Company and AN5568, also referred to as SCYX-7158, for human
African trypanosomiasis (HAT, or sleeping sickness), which is licensed to
Drugs for Neglected Diseases initiative, or DNDi. We also have a pipeline of
other internally discovered topical and systemic boron-based compounds in
development. For more information, visit http://www.anacor.com.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
dsheel@anacor.com
 
Press spacebar to pause and continue. Press esc to stop.